Posts Tagged ‘Nasodine’
Nasodine Phase 3 common cold trial underway
03 May 2022
Firebrick Pharma is pleased to announce that the first patient has been recruited into its confirmatory Phase 3 trial for Nasodine® Nasal Spray (“Nasodine”) as a treatment for the common cold. The randomised controlled Phase 3 trial expects to recruit up to 450 adult subjects with early cold symptoms to achieve a target treatment population…
Nasodine trial in COVID-19 started
26 Apr 2022
Firebrick Pharma is pleased to announce that the Phase 2 COVID-19 clinical trial for Nasodine® Nasal Spray (“Nasodine”) in South Africa has commenced, with the first patient now recruited.